A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
This research study is looking at a medication called vatiquinone for people living with Friedreich Ataxia. It's specifically for individuals who have previously taken part in another vatiquinone study. The main goal is to check the long-term safety of the medicine and see if it continues to be helpful over a longer period. This study allows participants to continue receiving vatiquinone, addressing a need for ongoing treatment. Researchers will be monitoring the effects of the medication over about three years. If you've been in a vatiquinone study before, this might be a way to keep receiving the treatment and contribute to understanding its long-term benefits.
Överblick
Vad handlar denna studie om?
This study is about a medicine called vatiquinone, which is being investigated for people who have a condition called Friedreich Ataxia. Friedreich Ataxia is a rare inherited disease that affects the nervous system, causing problems with movement and coordination.
The main aim of this study is to look at the long-term safety of vatiquinone. Since you would have been in a previous study with this medicine, the researchers want to continue watching how it affects you over a longer period. They also want to see if it continues to help with the symptoms of Friedreich Ataxia.
This study is designed to offer continued access to vatiquinone for people who have already used it in a clinical trial. This means that if you found the medicine helpful, you might be able to carry on taking it for about three years, while doctors continue to gather important information about its effects. This helps doctors understand if the medicine is a good long-term option for people with Friedreich Ataxia.
Viktiga punkter
- This study is for people with Friedreich Ataxia who have already used vatiquinone in a past study.
- It aims to check the long-term safety and effectiveness of vatiquinone over about three years.
- Participation means continued access to the study medicine and regular health check-ups.
- Contraception is required for men and women who could have children.
- You cannot be taking part in another treatment study or be pregnant/breastfeeding.
Vem kan vara berättigad?
To join this study, you must have Friedreich Ataxia and have already completed a previous research study involving the medicine vatiquinone. It's important that you move directly from that previous study into this one.
If you are a man or woman who could have children, you must agree to use effective contraception (birth control) throughout the study and for 30 days after your last dose of the medicine. This is to prevent pregnancy during the study.
You cannot join this study if you are already taking part in another clinical trial where you are receiving a treatment. Also, you cannot be pregnant or breastfeeding.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Do I have Friedreich Ataxia?
- Have I already completed a previous study with vatiquinone?
- Am I willing to use effective birth control if I could have children?
- Am I currently pregnant or breastfeeding?
- Am I participating in any other treatment study right now?
Vad innebär deltagande?
If you decide to take part, you will be given the study medicine, vatiquinone, which you would have taken in a previous study. You will continue to have regular check-ups with the study team over approximately three years. These visits will involve various tests and assessments to monitor your health, how the medicine is working, and to check for any side effects. The study team will explain exactly what each visit involves, but it's important to remember that this is a long-term commitment, likely involving regular trips to the clinic or hospital.
Potentiella risker och fördelar
Platser (14)
- UCLAVerifierat postnummerLos Angeles, USA
- Universitetet i FloridaVerifierat postnummerGainesville, USA
- University of South FloridaVerifierat postnummerTampa, USA
- University of IowaVerifierat postnummerIowa City, USA
- Barnsjukhuset i PhiladelphiaVerifierat postnummerPhiladelphia, USA
- Murdoch BarnforskningsinstitutVerifierat postnummerParkville, Australien
- University of Campinas (UNICAMP) - School of Medical Sciences, Dept of NeurologyVerifierat postnummerSão Paulo, Brasilien
- Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)Verifierat postnummerMontreal, Kanada
- CHU Sainte-JustineVerifierat postnummerMontreal, Kanada
- Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute)Verifierat postnummerParis, Frankrike
- Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE)Verifierat postnummerTübingen, Tyskland
- Ospedale Pediatrico Bambino Gesu' IRCCSVerifierat postnummerRom, Italien
Vanliga frågor
What is Friedreich Ataxia?
Friedreich Ataxia is a condition that affects the nervous system, causing problems with balance, coordination, and movement.
What is vatiquinone?
Vatiquinone is a medicine being studied to see if it can help people with Friedreich Ataxia.
Will I get the actual medicine or a dummy pill?
Because you've been in a previous study and this is continuing access, you will receive the actual medicine, vatiquinone.
Hur länge kommer studien att pågå?
This study is planned to last for about three years.
Kan jag lämna studien om jag ändrar mig?
Yes, you can leave the study at any time, and you don't have to give a reason. Your medical care won't be affected.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.